- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 503KB)
Pembrolizumab – March 2023
Pembrolizumab(early breast cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL vial; Keytruda®
Last updated
30 May 2025